Use of Injectable CAB/RPV LA as Replacement ART in Virally Suppressed Adults

August 2022

Table 2: Optional Lead-in, Initiation, and Maintenance for MONTHLY (every 4 weeks) CAB/RPV LA Dosing [a]

Timing	Dosing and Administration	Comments
Optional oral lead-in: Therapy Initiation: Week 0 (aka month 0)	CAB 30 mg/RPV 25 mg once daily by mouth with a meal x 4 weeks	Oral medication lead-in
Week 4 (aka month 1)	CAB 600 mg (3 mL)/RPV 900 mg (3 mL) IM injection	**Initiation dose:** Administer on last day of oral lead-in or prior suppressive ART regimen
Week 8 (aka month 2) and every 4 weeks (aka every 1 month) thereafter	CAB 400 mg (2 mL)/RPV 600 mg (2 mL) IM injection	**Maintenance dose:** Administer within 7 days before or after scheduled date (see Managing Missed or Delayed Injections)

Abbreviations: aka, also known as; ART, antiretroviral therapy; CAB, cabotegravir (brand name Vocabria); CAB/RPV LA, injectable long-acting cabotegravir/rilpivirine (brand name Cabenuva); IM, intramuscular; RPV, rilpivirine (brand name Edurant).

Note:

a. FDA. Cabenuva (cabotegravir extended-release injectable suspension; rilpivirine extended-release injectable suspension), co-packaged for intramuscular use. 2021 Jan. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212888s000lbl.pdf [accessed 2021 Mar 08]

Table 3: Optional Lead-in, Initiation, and Maintenance for BIMONTHLY (every 8 weeks) CAB/RPV LA Dosing [a,b]

Timing	Dosing and Administration	Comments
Optional oral lead-in: Therapy initiation: Week 0 (aka month 0)	CAB 30 mg/RPV 25 mg once daily by mouth with a meal x 4 weeks	Oral medication lead-in
Week 4 (aka month 1)	CAB 600 mg (3 mL)/RPV 900 mg (3 mL) IM injection	**Initiation dose:** Administer on last day of oral lead-in or prior suppressive ART regimen
Week 8 (aka month 2)	CAB 600 mg (3 mL)/RPV 900 mg (3 mL) IM injection	**Maintenance dose:** Administer within 7 days before or after scheduled date (see Managing Missed or Delayed Injections)
Week 16 (aka month 4) and every 8 weeks (aka every 2 months) thereafter	CAB 600 mg (3 mL)/RPV 900 mg (3 mL) IM injection	**Maintenance dose:** Administer within 7 days before or after scheduled date (see Managing Missed or Delayed Injections)

Abbreviations: aka, also known as; ART, antiretroviral therapy; CAB, cabotegravir (brand name Vocabria); CAB/RPV LA, injectable long-acting cabotegravir/rilpivirine (brand name Cabenuva); IM, intramuscular; RPV, rilpivirine (brand name Edurant).

Notes:

a. ViiV Healthcare. ViiV Healthcare announces US FDA approval of cabenuva (cabotegravir, rilpivirine) for use every two months, expanding the label of the first and only complete long-acting HIV treatment. 2022 https://viivhealthcare.com/hiv-news-and-media/news/press-releases/2022/january/viiv-healthcare-announces-fda-approval-of-cabenuva-for-use-every-two-months/ [accessed 2022 Feb 9]

b. FDA. Cabenuva (cabotegravir extended-release injectable suspension; rilpivirine extended-release injectable suspension), co-packaged for intramuscular use. 2021 Jan. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212888s000lbl.pdf [accessed 2021 Mar 8]